Samsung Biologics Strengthens Global Collaboration, Hosts 'Koinnovation Day'

Samsung Biologics announced that it held the 'Co-Innovation Day' to strengthen mutual growth with global partners at its headquarters in Songdo, Incheon on the 13th and 14th.

Samsung Biologics announced that it held the 'Co-Innovation Day' to strengthen mutual growth with global partners at its headquarters in Songdo, Incheon on the 13th and 14th.
[Photo by Samsung Biologics]

Four global partners of Samsung Biologics?Merck, Cytiva, Sartorius, and Thermo Fisher Scientific?were invited to this event. Employees from Samsung Biologics and its partners enhanced their understanding of each company and explored collaboration methods through various programs such as seminars and exhibitions, thereby strengthening networking.

The 'Bio Technology Seminar,' organized to share biopharmaceutical production technologies and market trends, featured two topics selected by each partner, totaling eight sessions. Topics included ▲ Thermo Fisher Scientific’s “Innovative Chinese Hamster Ovary (CHO) Cell Culture Methods,” ▲ Sartorius’s “Chromatography Technology and Global Bio Industry Trends,” and ▲ Cytiva’s “Antibody-Drug Conjugate (ADC) Process,” which are gaining attention in biopharmaceutical production research. Approximately 400 employees from related departments within Samsung Biologics, including manufacturing, quality operations, and contract development (CDO), participated in the seminar to share expertise and discuss ways to advance technology.

At the exhibition booths, partners showcased their latest materials and equipment, such as Thermo Fisher Scientific’s single-use bioreactors and single-use centrifuges, and Merck’s chromatography systems. The booths were operated continuously to allow all Samsung Biologics employees to visit freely. By enabling not only viewing but also hands-on experience with the equipment, the event aimed to increase employees’ interest in and understanding of partner products.

John Rim, CEO of Samsung Biologics, stated, “Samsung Biologics’ continuous growth as a global contract development and manufacturing organization (CDMO) has been possible thanks to strong mutual cooperation with our partners. We will continue to lead ESG (Environmental, Social, and Governance) management culture in the pharmaceutical and bio industries through various activities for mutual growth.”

Choi Junho, CEO of Cytiva Korea, said, “This year’s Co-Innovation Day was a meaningful time to introduce the latest technologies and solutions to experts leading the biopharmaceutical industry and to explore ways to collaborate. As a partner contributing to customers’ research, development, and production processes, we will continue to work closely and strive to solve challenges faced by customers and support the growth of Samsung Biologics and the Korean bio industry.”

This content was produced with the assistance of AI translation services.